BioLineRx Ebitda from 2010 to 2024

BLRX Stock  USD 0.29  0.01  3.57%   
BioLineRx EBITDA yearly trend continues to be fairly stable with very little volatility. EBITDA is likely to outpace its year average in 2024. During the period from 2010 to 2024, BioLineRx EBITDA regression line of annual values had r-squared of  0.69 and arithmetic mean of (23,597,345). View All Fundamentals
 
EBITDA  
First Reported
2010-03-31
Previous Quarter
3.3 M
Current Value
-3.4 M
Quarterly Volatility
4.7 M
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check BioLineRx financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among BioLineRx's main balance sheet or income statement drivers, such as Depreciation And Amortization of 1.5 M, Interest Expense of 2.3 M or Selling General Administrative of 17.5 M, as well as many indicators such as Price To Sales Ratio of 10.09, Dividend Yield of 0.0 or PTB Ratio of 8.27. BioLineRx financial statements analysis is a perfect complement when working with BioLineRx Valuation or Volatility modules.
  
Check out the analysis of BioLineRx Correlation against competitors.
For more information on how to buy BioLineRx Stock please use our How to Invest in BioLineRx guide.

Latest BioLineRx's Ebitda Growth Pattern

Below is the plot of the Ebitda of BioLineRx over the last few years. It is BioLineRx's EBITDA historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in BioLineRx's overall financial position and show how it may be relating to other accounts over time.
Ebitda10 Years Trend
Slightly volatile
   Ebitda   
       Timeline  

BioLineRx Ebitda Regression Statistics

Arithmetic Mean(23,597,345)
Geometric Mean21,222,454
Coefficient Of Variation(66.48)
Mean Deviation10,336,604
Median(21,993,000)
Standard Deviation15,686,656
Sample Variance246.1T
Range63.7M
R-Value(0.83)
Mean Square Error82.1T
R-Squared0.69
Significance0.0001
Slope(2,914,309)
Total Sum of Squares3445T

BioLineRx Ebitda History

2024-54.2 M
2023-57.1 M
2022-28.5 M
2021-25.3 M
2020-22 M
2019-26.9 M
2018-26.9 M

About BioLineRx Financial Statements

BioLineRx investors use historical fundamental indicators, such as BioLineRx's Ebitda, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in BioLineRx. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
EBITDA-57.1 M-54.2 M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for BioLineRx Stock Analysis

When running BioLineRx's price analysis, check to measure BioLineRx's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy BioLineRx is operating at the current time. Most of BioLineRx's value examination focuses on studying past and present price action to predict the probability of BioLineRx's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move BioLineRx's price. Additionally, you may evaluate how the addition of BioLineRx to your portfolios can decrease your overall portfolio volatility.